Dernièrement…

🏆 #Amoéba remporte l’Innovation Award
A l’occasion de la 3ème édition du #symposium @PBioprotech, les équipes d’Amoéba ont eu le plaisir de voir leur travail récompensé ! Un grand merci au jury pour avoir choisi notre #innovation #biocontrôle parmi les 11 candidats !

#Amoéba au @PBioprotech de Reims 🌱
Du 28 au 30 juin, notre directrice #scientifique Sandrine Demanèche représentera #Amoéba au Plant BioProTech à Reims, et y présentera notre #innovation #biocontrôle devant plus de 300 intervenants de la communauté #scientifique.

📣 Communiqué de Presse : https://bit.ly/3NOLUON
#Amoéba annonce l’émission de la cinquième tranche de 60 obligations convertibles en actions (#OCA) dans le cadre de son financement obligataire avec programme d’intéressement conclu avec @niceandgreen_sa.

🌧 Suite aux violents épisodes #orageux et #grêleux de ce week end de la Pentecôte dans plus de 65 #départements, #Amoéba souhaite exprimer son soutien à tous les #agriculteurs dont les cultures ont été endommagées.

Amoéba: US regulatory calendar update

Amoéba updates the regulatory calendar for both the biocide and biocontrol applications in the US.

Lyon (France), May 30, 2022 – 17h45 – AMOÉBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, updates the regulatory calendar for both the biocide and biocontrol applications in the US.

Application for authorization of the biocide in the United States

The application for approval of the biocidal active substance, the living amoeba Willaertia magna C2c Maky, and biocidal products containing it, filed in April 2021 with the U.S. Environmental Protection Agency (U.S. EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by mid-2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.

Application for authorization of the biocontrol in the United States

The application for approval of the biocontrol active substance, the lysate of Willaertia magna C2c Maky, and the biocontrol products containing it, filed in October 2020 with the U.S. Environmental Protection Agency (EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by the end of May 2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.